Organization | Stryker

Stryker Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: Kalamazoo Michigan United States (1941)

Status: No NME R&D (1941)

Organization Overview

First Clinical Trial

2005

NCT00586976

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Drugs in Phase 4 Trials (1)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 3 Trials (4)

Key: Stryker (2) Acquired (2)

chlorhexidine (hibitane) (6 trials)

indocyanine green (ic-green) (5 trials)

ropivacaine (naropin) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (5)

Key: Stryker (2) Acquired (3)

acetaminophen (tylenol) (1 trial)

becaplermin (regranex) (1 trial)

betamethasone (celestone) (1 trial)

bmp7 (2 trials)

lidocaine (xylocaine) (1 trial)

Drugs in Other Trials (3)

Key: Stryker (1) Acquired (2)

alteplase (Activase) (1 trial)

cefazolin (ancef) (1 trial)

ceftriaxone (rocephin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acalculous Cholecystitis (Phase 1)

Cholangitis (Phase 1)

Cholecystitis (Phase 1)

Cholecystitis, Acute (Phase 1)

Cognitive Dysfunction (Phase 2)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Osteoarthritis (Phase 4)

Osteoarthritis, Hip (Phase 4)

Osteoarthritis, Knee (Phase 2)

Surgical Wound Infection (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 20
# of Trial APIs: 13